Early formation of mature amyloid‐β protein deposits in a mutant APP transgenic model depends on levels of Aβ1–42
Top Cited Papers
- 2 November 2001
- journal article
- research article
- Published by Wiley in Journal of Neuroscience Research
- Vol. 66 (4), 573-582
- https://doi.org/10.1002/jnr.1247
Abstract
The main objective of the present study was to develop an alternative singly‐transgenic (tg) hAPP model where amyloid deposition will occur at an earlier age. For this purpose, we generated lines of tg mice expressing hAPP751 cDNA containing the London (V717I) and Swedish (K670M/N671L) mutations under the regulatory control of the murine (m)Thy‐1 gene (mThy1‐hAPP751). In the brains of the highest (line 41) and intermediate (lines 16 and 11) expressers, high levels of hAPP expression were found in neurons in layers 4–5 of the neocortex, hippocampal CA1 and olfactory bulb. As early as 3–4 months of age, line 41 mice developed mature plaques in the frontal cortex, whereas at 5–7 months plaque formation extended to the hippocampus, thalamus and olfactory region. Ultrastructural and double‐immunolabeling analysis confirmed that most plaques were mature and contained dystrophic neurites immunoreactive with antibodies against APP, synaptophysin, neurofilament and tau. In addition, a decrease in the number of synaptophysin‐immunoreactive terminals was most prominent in the frontal cortex of mice from line 41. Mice from line 11 developed diffuse amyloid deposits at 11 months of age, whereas mice from line 16 did not show evidence of amyloid deposition. Analysis of Aβ by ELISA showed that levels of Aβ1–40 were higher in mice that did not show any amyloid deposits (line 16), whereas Aβ1–42 was the predominant species in tg animals from the lines showing plaque formation (lines 41 and 11). Taken together this study indicates that early onset plaque formation depends on levels of Aβ1–42. J. Neurosci. Res. 66:573–582, 2001.Keywords
This publication has 43 references indexed in Scilit:
- Transgenic Mouse Models of Alzheimer's DiseaseAnnals of the New York Academy of Sciences, 2000
- Expression of Human Apolipoprotein E3 or E4 in the Brains ofApoe−/−Mice: Isoform-Specific Effects on NeurodegenerationJournal of Neuroscience, 1999
- Neocortical synapse density and Braak stage in the Lewy body variant of Alzheimer disease: a comparison with classic Alzheimer disease and normal aging.Journal of Neuropathology and Experimental Neurology, 1998
- Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor ProteinsNeuron, 1997
- Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic miceNature Medicine, 1997
- Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In VivoNeuron, 1996
- Expression of APP in transgenic mice: a Comparison of neuron-specific promotersNeurobiology of Aging, 1996
- A simple dot-immunobinding assay for quantification of synaptophysin-like immunoreactivity in human brain.Journal of Histochemistry & Cytochemistry, 1994
- Expression patterns of β‐amyloid precursor protein (β‐APP) in neural and nonneural human tissues from alzheimer's disease and control subjectsAnnals of Neurology, 1991
- Patterns of gliosis in alzheimer's disease and aging cerebrumGlia, 1989